Compare Amgen, Inc. (AMGN) vs Brunswick Corporation (BC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Brunswick Corporation — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while Brunswick Corporation trades at $76.79 (market cap $5.06B). The key difference: Amgen, Inc. is far larger — about 38.8× Brunswick Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | BC | |
|---|---|---|
Market Cap | $196.12B | $5.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $89.22 |
52-Week Low | $271.18 | $56.64 |
Enterprise Value | $241.41B | $7.22B |
Dividend Yield | 2.77% | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BC trades at $77.9, down 0.12% on the day, with a bearish technical signal but strong analyst support. The stock shows mixed fundamentals with a high P/E of 73.92 and negative net income margin of -2.47%, though revenue remains stable near $5.4 billion. Recent news highlights operational updates and expansion milestones, including Freedom Boat Club's 450th location opening (GlobeNewsWire, June 23, 2026).
Outlook is cautiously optimistic given the 71% buy rating from analysts and an $86.40 consensus price target, but risks include persistent negative profitability and high debt levels. The upcoming Q2 2026 earnings report on July 30, 2026 (GlobeNewsWire, July 9, 2026) will be critical for confirming turnaround potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →
